Michael Morabito
Stock Analyst at Chardan Capital
(n/a)
# 4,464
Out of 4,862 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $55.62 | +45.63% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $295.57 | -31.32% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.63 | +12,665.28% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $10.41 | +812.58% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $26.08 | -23.31% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $55.62
Upside: +45.63%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $295.57
Upside: -31.32%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.63
Upside: +12,665.28%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $10.41
Upside: +812.58%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $26.08
Upside: -23.31%